Abuse liability of centrally acting non-opioid analgesics and muscle relaxants - A brief update based on a comparison of pharmacovigilance data and evidence from the literature

11Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

There is a lack of data regarding the abuse liability of centrally acting non-opioid analgesics (NOA) and muscle relaxants (MR). A comparison of data retrieved from a German pharmacovigilance database (BfArM; accessed May 2013) and data from the literature concerning the abuse liability of NOA and MR approved in Germany was performed. The BfArM-database demonstrated cases of abuse only for clonidine and paracetamol, whereas the literature suggests evidence for an abuse potential of baclofen, clonidine, ketamine, metamizole, methocarbamol, orphenadrine, paracetamol, propyphenazone, and tizanidine. The low number of detected cases in the BfArM-database could be a result of under-reporting. © CINP 2014.

Cite

CITATION STYLE

APA

Gahr, M., Freudenmann, R. W., Eller, J., & Schönfeldt-Lecuona, C. (2014). Abuse liability of centrally acting non-opioid analgesics and muscle relaxants - A brief update based on a comparison of pharmacovigilance data and evidence from the literature. International Journal of Neuropsychopharmacology, 17(6), 957–959. https://doi.org/10.1017/S1461145713001600

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free